Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > NEW INDICATION FOR ENYITAN® (OMALIZUMAB FOR INJECTION) OBTAINS MARKETING APPROVAL

NEW INDICATION FOR ENYITAN® (OMALIZUMAB FOR INJECTION) OBTAINS MARKETING APPROVAL

February 10, 2025

a250210a_00.png

a250210a_01.png

Next: SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat